Physician profile
Robert A Young
NPI 1245229715
$8,808.78
in general payments reported to CMS, 2019-2025
25 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,353 · 2022: $1,983 · 2023: $1,658 · 2024: $2,170 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,978 · Food and Beverage: $2,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,977.70 |
| Food and Beverage | $2,494.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $3,969.36 | 2022-2025 | (8269) Dreamstation Cpap, Dreamstation Cpap |
| Abbvie INC. | $1,185.10 | 2021-2025 | |
| Novo Nordisk INC | $785.31 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $588.34 | 2021-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $539.03 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $507.43 | 2021-2025 | Farxiga, Breztri, Bevespi Aerosphere |
| Pfizer INC. | $308.16 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $138.60 | 2024 | Xdemvy |
| Glaxosmithkline, LLC. | $135.45 | 2021-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $93.47 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Kowa Pharmaceuticals America, INC. | $84.44 | 2021-2023 | Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $79.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $69.48 | 2022-2023 | Ajovy |
| Hologic Sales and Service, LLC | $44.88 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $43.21 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $34.35 | 2021 | |
| Azurity Pharmaceuticals, INC. | $33.65 | 2023 | Edarbi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.42 | 2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $23.67 | 2022 | |
| Astellas Pharma US INC | $22.76 | 2024 | Veozah |
| Sanofi Pasteur INC. | $22.40 | 2025 | |
| Bausch Health US, LLC | $22.00 | 2022 | |
| Eisai INC. | $20.05 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.45 | 2024 | Xifaxan |
| Medtronic, INC. | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.